The best part is that this news has not caused a spike in the pre market trading, and will likely not cause one once the market opens. So every share collected under a dollar is a gift in my opinion. By end of December there should be plenty of reason to celebrate this stock. FDA will comment on the osteoarthritis of the knee (OAK): The amendment to the OAK Phase III clinical trial (AP-013), that harmonizes the FDA agreement on the Special Protocol Assessment (SPA) with FDA guidance for clinical trials on hold due to COVID-19, has been received by the FDA. The FDA notified the Company that a formal response will be provided by the end of this year.
Put that with the results of the next Phase study of the Nebulizer, remember its only a 5 day trial and 3 day follow up for results, so there wont be the usual 6 to 8 months to get results and notification from the FDA on how they view the results.
News 
Market Data 
Discover 
